Jacob Bell is a Senior Reporter at BioPharma Dive. He specializes in covering themes related to medicine and healthcare, pharmaceuticals, and sports, with a focus on topics such as pharmaceutical manufacturing, regulation, and competitive sports. Jacob's work has been featured in notable publications including BioPharma Dive, PharmaVoice, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jacob Bell's coverage is heavily focused on the healthcare and pharmaceutical industries, with particular attention to biotechnology. His articles often incorporate press releases and data citations, indicating a preference for factual and industry-specific information.
Given his focus on private sector announcements, Jacob may be interested in pitches related to new product launches, significant investments or acquisitions within the healthcare and biotech sectors. Furthermore, he might be open to expert commentary from professionals well-versed in various aspects of biotechnology, pharmaceuticals, neurological diseases such as ALS research or gene therapy.
As there is no specific geographic focus mentioned for Jacob's coverage area, it would be beneficial to provide globally relevant insights pertaining to the topics covered.
This information evolves through artificial intelligence and human feedback. Improve this profile .
In fact, the former lost tens of billions of dollars in market value following reports of a tie-up between the pharmaceutical giants.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter
Pair of Dores will tee off in top amateur event Tuesday
Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.
An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.
The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
By: Jacob Bell
Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.
Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
Vanderbilt alumnae Auston Kim will represent Team USA in September
